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Conclusions. These data suggest that anemia is associated with reduced QoL in 
patients with HF. Additional studies will be required to establish if this is a cause and 
effect relationship.
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1144-103 Chronic Infusion of Bradykinin Preserves Vascular 
Nitric Oxide-Mediated Endothelial Function and Limits 
the Alteration in Left Ventricular Function During 
Pacing-Induced Heart Failure in Conscious Dogs
Jinbo Su, Daniel Tonduangu, Bijan Ghaleh, Philippe Le Corvoisier, Fanny Vincent, 
Thierry Badoual, Lucien Sambin, Alain Berdeaux, Bertrand Crozatier, Luc Hittinger, 
INSERM, Créteil, France, INSERM, Kremlin-Bicêtre, France
It has been shown that bradykinin (BK) is involved in the beneficial effects of angiotensin-
converting enzyme inhibitors on vascular endothelial and left ventricular (LV) functions in
heart failure (HF). However, it is not known whether BK per se exerts a protective action
on vascular and cardiac functions during the development of HF. This study examined the
effects of chronic BK infusion on cardiac and vascular nitric oxide (NO)-mediated endot-
helial functions during pacing-induced HF in conscious dogs. Sixteen beagle dogs were
chronically instrumented to measure cardiac output, LV pressure, LV wall thickness and
left and right atrial and aortic pressures. After baseline recording and examining the
vasodilator responses to intravenous acetylcholine (ACh, 0.3-3 µg/kg) and nitroglycerin
(NTG, 1-10 µg/kg) in the control state, dogs were randomized to receive through left atria
either water (vehicle group) or BK (1 µg/min, which does not change systemic hemody-
namics; BK group) during right ventricular pacing (250 beats/min, 5 weeks). The vasodi-
lator responses to ACh and NTG were again examined after 3 and 5 weeks of pacing.
The expression of endothelial NO synthase (eNOS) in femoral, carotid and renal arteries
was determined by Western blot analysis. After 3 weeks of pacing, the BK group had a
lesser degree of HF than the vehicle group as indicated by less alterations in LV end-
diastolic pressure (+10±3 vs +19±2 mmHg, p<0.05), LV wall thickening (-33±18 vs -
75±9%, p<0.05) and cardiac output (-16±6 vs -32±6%, p<0.05). Total peripheral resis-
tance (TPR) increased in the vehicle group (+18±10%, p<0.05) but remained unchanged
in the BK group (+1±8%). In both groups during HF, TPR response to NTG was not
altered. In contrast, TPR response to ACh was blunted in the vehicle group (p<0.01) but
was unchanged in the BK group. Similar trends were also observed after 5 weeks of pac-
ing. In all examined arterial beds, eNOS protein expression decreased significantly in the
vehicle group but was preserved in the BK group. Thus, in conscious dogs, chronic BK
infusion limits alterations in LV function and preserves vascular endothelial NO-mediated
vasodilation and thereby delays the progression of HF.
1144-104 The Novel Organic Nitroxyl Donor, Isopropylamine/Nitric 
Oxide Exerts Beta-Independent Positive Inotropy/
Lusitropy in Failing Hearts
Tatsuo Katori, Carlo G. Tocchetti, Katrina M. Miranda, Hunter C. Champion, Jon M. 
Fukuto, David A. Wink, David A. Kass, Nazareno Paolocci, The Johns Hopkins 
University, Baltimore, MD, National Institutes of Health, Bethesda, MD
BackGround: The Nitroxyl (HNO/NO-) donor Angeli’s salt (AS) is a potent inotropic/lusi-
tropic agent both in healthy and heart failure dogs. Its action linked in part to activation of
non-adrenergic/non-cholinergic (NANC) fibers to release calcitonin gene-related peptide
(CGRP). However, AS chemistry may involve generation of other NO-related species, i.e.
nitrates. To more specifically assess HNO/NO- signaling, we developed and tested a
novel organic compound isopropylamine/NO (IPA/NO), a near pure (>95%) HNO/NO-
donor.
Methods: Pressure-volume relations were assessed in conscious dogs under basal con-
ditions and after induction of heart failure (HF) by tachypacing.
Results: IPA/NO (5µg/kg/min) increased contractility (end-systolic elastance, Ees,) by
58.0±8.1% (p<0.001) in control and 46.8±10.2% (p<0.01) in HF, and lowered preload and
afterload similarly in healthy and CHF dogs. This contrasted to negative inotropic effects
from equidilative doses of diethylamine/NO (DEA/NO, pure NO donor, 2µg/kg/min), S-
Nitrosoglutathione (GSNO, pure NO doror, 0.625µg/kg/min) or nitroglycerin (NTG, 10µg/
kg/min). Isovolumic relaxation was 6.1±3.8% faster with IPA/NO in control hearts, and
this effect was more pronounced in HF (28.3±6.4%; p<0.05 vs. control hearts). Co-infu-
sion of dobutamine with IPA/NO further augmented contractility by 46.0±16% (p<0.05) in
control and 31.4+/-6.5% (p<0.05) in HF above dobutamine alone, whereas DEA/NO,
GSNO or NTG blunted β-stimulation. IPA/NO inotropic/lusitropic action was unaffected by
β-blockade (timolol, 2mg/kg). IPA/NO increased arterial plasma CGRP (30.3±6.0 to
65.1±2.8 pg/ml; p<0.005) and neurotensin (78.6±7.3 to 170.0±25.3pg/ml; p<0.01),
reflecting NANC stimulation. Responses to IPA/NO were very similar to those previously
reported from AS.
Conclusion: The novel HNO/NO- donor, IPA/NO, has potent inotropic and lusitropic
effects in failing hearts that are synergistic with β-agonist stimulation. Unlike inorganic
AS, this new organic compound has potential for clinical development as an NO-related
species with both vasoactive and cardiotropic effects, for use in the treatment of heart
failure.
1144-127 Effects of Inotropic Stimulation on Left Ventricular 
Torsional Deformation in Tachycardia-Induced Dilated 
Cardiomyopathy
Filiberto Rodriguez, Katherine B. Harrington, Frederick A. Tibayan, Paul Dagum, Frank 
Langer, George T. Daughters, Neil B. Ingels, Jr., D. Craig Miller, Stanford University, 
Stanford, CA, Palo Alto Medical Foundation, Palo Alto, CA
Introduction: Tachycardia-induced cardiomyopathy (TIC) is accompanied by decreased
and delayed systolic left ventricular (LV) torsion and loss of early diastolic recoil, which
may contribute to LV dysfunction by increasing systolic transmural strain gradients and
impairing diastolic filling. To gain more mechanistic understanding of the pathophysiology
of this model of congestive heart failure (CHF), we examined the effects of inotropic stim-
ulation on torsional deformation at baseline and after the development of TIC.
Methods: Seven sheep had radiopaque markers implanted in the LV subepicardium to
measure: 1.) maximal systolic torsion (Φmax); and, 2.) diastolic torsion recoil during the
first 5% of filling (Φ5%) using biplane videofluoroscopy (60 Hz) one week after surgery,
before and during inotropic stimulation with dobutamine. Rapid ventricular pacing was
then implemented for 15±6 days to create TIC, and data were again acquired before and
during dobutamine infusion.
Results: Maximal torsion and recoil rate were restored to near-normal levels in TIC with
dobutamine (Table).
Conclusions: Inotropic stimulation with dobutamine may benefit patients with CHF, in
part, by restoring LV torsion dynamics, which may decrease systolic transmural strain
gradients and augment early-diastolic filling.
QoL
unadjusted 
scores
(mean±SD)
Anemia
(n)
Hgb Group (g/dl)
(n)
Yes
(257)
No
(523)
P* <12
(191)
12-12.9
(158)
13-13.9
(156)
>14
(275)
P†
KCCQ 
Functional 
Status
55 ± 22 60 ± 22 0.006 54 ± 22 56 ± 22 58 ± 22 64 ± 21 <0.001
Symptoms 58 ± 24 63 ± 24 0.006 56 ± 24 59 ± 24 62 ± 23 66 ± 24 <0.001
Clinical 56 ± 21 59 ± 21 0.022 54 ± 21 56 ± 20 58 ± 22 62 ± 20 <0.001
MLHF
Physical 19 ± 11 18 ± 12 0.041 20 ± 11 19 ± 11 18 ± 12 16 ± 11 0.003
Emotional 10 ± 
7.7
9.3 ± 
7.7
0.222 10 ± 
7.8
10 ± 
8.0
9.7 ± 
8.0
8.8 ± 
7.3
0.227
Summary 44 ± 26 41 ± 26 0.154 45 ± 26 44 ± 26 43 ± 27 39 ± 26 0.061
*P value from t-test, †P value from ANOVA. Both analyses based on unadjusted QoL 
scores.
preTIC TIC
HEMODYNAMICS preDobutami
ne
Dobutami
ne
preDobutami
ne
Dobutami
ne
Heart Rate (min-1) 115±19 146±14* 125±14 171±38*
dP/dtmax (mmHg/s) 1,850±458 3,170±828
*
1,530±468† 2,420±506
*
LVPmax (mmHg) 110±11 129±15* 115±13 127±17*
LVEDP (mmHg) 17±8 18±11 38±7† 42±11
LVESP (mmHg) 88±12 95±10 93±14 100±19
LVEDV (mL) 178±17 163±13* 226±19† 224±21
LVESV (mL) 139±15 123±8 189±21† 185±28
